Results 221 to 230 of about 196,164 (338)

Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab. [PDF]

Front Immunol
Naidu V, Jain HA, Yalcinkaya A, Charavanamuttu Y, Biswas D, Ali N, Mee JB, Chauhan J, Semkova K, Benton EC, Karagiannis SN, Setterfield J, Groves RW, Tull TJ.   +13 more
europepmc   +1 more source

PCN64 Evaluating the Cost-Effectiveness of the Addition of Rituximab to Chemotherapy in the First Line Treatment of Follicular Lymphoma Patients in the UK [PDF]

, 2011
Rachid Rafia, Diana Papaioannou, Matt Stevenson, John Rathbone, Helen Buckley Woods   +4 more
openalex   +1 more source

An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations

Small Methods, EarlyView.
This work presents an integrated set of methods to evaluate the efficacy of asparaginase formulations against B‐cell Acute Lymphoblastic Leukemia (ALL) in mice, including the establishment of an ALL murine model, an amino acid depletion study using high‐performance liquid chromatography (HPLC), and comprehensive assessment of antibody production ...
Julien Santelli, Annie Y. Heble, Connor Endsley, Adam Woodward, Nazia Hafeez, Naomi Winick, Jacques Lux   +6 more
wiley   +1 more source

THU0194 Cd4+ t cells, immunoglobulins and risk of infection in patients with rheumatoid arthritis over multiple cycles of rituximab [PDF]

, 2018
Fernando Martins, Amina Bensalem, Théodora Bejan‐Angoulvant, A. Lhommas, J Melet, S. Mammou, Gilles Thibault, L. Bernard, P. Goupille, Denis Mulleman   +9 more
openalex   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis. [PDF]

Cancers (Basel)
Pelliccia S, Banchi M, De Marchi L, Cencini E, Seimonte C, Fabbri A, Nunzi A, Destefano S, Bocci G, Cox MC.   +9 more
europepmc   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Fatal interstitial lung disease associated with rituximab in diffuse large B-cell lymphoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Li L, Liu F, Zhou J, Chen XL.
europepmc   +1 more source

Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial.

, 2020
Karen R. Armbrust, Austin Fox, Brett G. Jeffrey, Patti Sherry, H. Nida Sen   +4 more
openalex   +2 more sources

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Journal of the American Society of Nephrology, 2017
K. Dahan, H. Dębiec, E. Plaisier, M. Cachanado, A. Rousseau, Laura Wakselman, P. Michel, Fabrice Mihout, B. Dussol, M. Matignon, C. Mousson, T. Simon, P. Ronco   +12 more
semanticscholar   +1 more source